TY - JOUR
T1 - Azathioprine for people with multiple sclerosis
AU - Nonino, Francesco
AU - Baldin, Elisa
AU - Ridley, Ben
AU - Casetta, Ilaria
AU - Iuliano, Gerardo
AU - Filippini, Graziella
N1 - Publisher Copyright:
Copyright © 2021 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
PY - 2021/7/16
Y1 - 2021/7/16
N2 - Objectives: This is a protocol for a Cochrane Review (intervention). The objectives are as follows:. The objectives of the review are to estimate the benefits and harms of:. azathioprine (AZA) compared with placebo or other disease -modifying treatments (DMTs) as first-choice treatment for relapsing forms of multiple sclerosis (MS); AZA compared with placebo or other DMTs for relapsing forms of MS when switching from another DMT; AZA compared with placebo or other DMTs as first-choice treatment for progressive forms of MS; and AZA compared with placebo or other DMTs for progressive forms of MS when switching from another DMT.
AB - Objectives: This is a protocol for a Cochrane Review (intervention). The objectives are as follows:. The objectives of the review are to estimate the benefits and harms of:. azathioprine (AZA) compared with placebo or other disease -modifying treatments (DMTs) as first-choice treatment for relapsing forms of multiple sclerosis (MS); AZA compared with placebo or other DMTs for relapsing forms of MS when switching from another DMT; AZA compared with placebo or other DMTs as first-choice treatment for progressive forms of MS; and AZA compared with placebo or other DMTs for progressive forms of MS when switching from another DMT.
UR - http://www.scopus.com/inward/record.url?scp=85110723194&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85110723194&partnerID=8YFLogxK
U2 - 10.1002/14651858.CD015005
DO - 10.1002/14651858.CD015005
M3 - Article
AN - SCOPUS:85110723194
SN - 1361-6137
VL - 2021
JO - Cochrane Database of Systematic Reviews
JF - Cochrane Database of Systematic Reviews
IS - 7
M1 - CD015005
ER -